{
    "id": 2486,
    "fullName": "AURKA over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "AURKA over exp indicates an over expression of the Aurka protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6790,
        "geneSymbol": "AURKA",
        "terms": [
            "AURKA",
            "AIK",
            "ARK1",
            "AURA",
            "BTAK",
            "PPP1R47",
            "STK15",
            "STK6",
            "STK7"
        ]
    },
    "variant": "over exp",
    "createDate": "10/28/2014",
    "updateDate": "10/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1042,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237) prevented Aurka induced resistance to Nolvadex (tamoxifen) in breast cancer cell lines (PMID: 24166501).",
            "molecularProfile": {
                "id": 2350,
                "profileName": "AURKA over exp"
            },
            "therapy": {
                "id": 1474,
                "therapyName": "Alisertib + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 753,
                    "pubMedId": 24166501,
                    "title": "Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ER\u03b1 in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24166501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16062,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with metastatic small-cell neuroendocrine prostate cancer with Aurka and Mycn protein overexpression and focal deletions in CDKN2A, CDKN2B, RB1, and BRCA2 tumor suppressor genes, had complete response of metastatic lesions and a sustained 8.3 month partial response to Alisertib (MLN8237) therapy prior to disease recurrence in the brain (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 31394,
                "profileName": "AURKA over exp MYCN over exp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16064,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with metastatic small-cell neuroendocrine prostate cancer with Aurka and Mycn protein overexpression, deletions of FBXW7, FANCA, and SMARCB1, and loss of PTEN and CDKN2A, responded to Alisertib (MLN8237) therapy with complete resolution of metastasis in 12 weeks and a 14-month complete radiological response prior to discontinuation of therapy due to illness (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 31395,
                "profileName": "AURKA over exp FBXW7 del MYCN over exp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2350,
            "profileName": "AURKA over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 2346,
                    "name": "AURK Inhibitor (Pan)",
                    "profileName": "AURKA over exp"
                },
                {
                    "id": 2347,
                    "name": "Aurka Inhibitors",
                    "profileName": "AURKA over exp"
                }
            ]
        },
        {
            "id": 31394,
            "profileName": "AURKA over exp MYCN over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31395,
            "profileName": "AURKA over exp FBXW7 del MYCN over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}